Speakers: Dawn Dufield (KCAS Bio), Hetal Sarvaiya (Stemcentrx Abbvie), Jessy Fan (Amgen), Richard Seipert (Genentech), Yihan Li (Sciex), Suk Hyung (Genentech), Jintang He (Genentech)
Organizers: Keyang Xu and Surinder Kaur (Genentech)
Date: 2018-11-16
Time: 8:45-17:00 Pacific Time
Registration fee: (USD): Regular: $195; Academic: $125; For unemployed or students: $30; For vendor-show rep: $35; For major-sponsor rep (incl lunch): $0
Location: SF Bay Area: Foster City Crowne Plaza
Major Sponsor: (2)Catalent Pharma Solutions; Celerion
Vendor show vendors registered to date: (9)Alturas Analytics; Intertek; KCAS Bio; QPS; SCIEX; STC Biologics.com; Tecan SP; Thermo Fisher Scientific, SID; Waters
Registration: http://www.PBSS.org
Registration deadline:2018-11-14  (it will close sooner if the seating cap is reached)

About the Topic

Dawn Dufield
Dr. Dawn Dufield is the Director, BioPharma Services at KCAS. She received her Ph.D. in Chemistry from the University of Kansas. She joined Monsanto in 1997 which transitioned into Pfizer in 2004. She has been with Pfizer and legacy companies for over 20 years. Dr. Dufield has been working in the LC-MS/MS field since 1997. She has extensive experience in developing qualitative and quantitative LC-MS/MS assays for both large and small molecules. She has developed numerous assays using both traditional and immunoaffinity enrichment approaches. She was one of the early pioneers of using immunoaffinity combined with LC-MS/MS to offer additional selectivity which is now commonly referred to as Hybrid LCMS. She currently is a member of the AAPS Mass Spec Protein Bioanalysis Committee (MSPBC) and an active member of ASMS. She has numerous publications and presentations in her field and recently contributed to a white paper on recommendations for validation of LCMS based bioanalytical methods for protein biotherapeutics.

Hetal Sarvaiya (Abbvie-Stemcentrx)
Ms. Hetal Sarvaiya is currently a Senior Scientist III at Stemcentrx Abbvie LLC, leading the research mass-spec group and LC-MS ADC platform team to support a variety of different ADC programs from research to development. She received her Masters in Biomedical Engineering from Virginia Tech. Prior to joining Stemcentrx, Ms. Sarvaiya also worked at Momenta Pharmaceuticals and Merck. She has 12+ years of industry experience in developing LC-MS based methods for qualitative and quantitative bioanalysis of different biotherapeutics modalities (mAbs, bispecifics, fusion proteins, nanobodies, and ADCs), as well as biosimilars. Her research work has also covered proteomics and glycomics platform development to support translational research studies. Recently, her focus is to evaluate the stability of different linker drugs and conjugations as well as develop robust quantitative assays for total antibody and conjugated antibody read-outs from in-vivo pharm/tox studies.

Jessy Fan (Amgen)
Dr. Jessy Fan is currently a Scientist at Amgen. She finished her graduate study in ETH Zurich, Switzerland, focusing on the mechanism of protein glycosylation. She then got her industry exposure as a postdoc at Pfizer, and continued to worked in the PKDM department as a Senior Scientist. She later moved to Amgen in 2016. Dr. Fan has strong and broad expertise in mass spectrometry quantification and characterization of large molecules ( protein/peptide, glycolipid, carbohydrate) and small molecules. Her responsibilities cover designing, executing, and staff training for IND-enabling PKDM activities mainly for protein therapeutics programs, including PK/PD, target engagement, mechanism of action (MOA), biodistribution analysis etc.

Richard Seipert (Genentech)

Dr. Richard Seipert is currently a Senior Scientist at Genentech. He is a bioanalytical chemist with 10 years of experience in the biotechnology industry. His experience includes mass spectrometry and chromatography based method development, method validation, and control system strategy. He also has experience managing and has served as analytical and technical team leader for several early stage projects in addition to coaching direct reports and mentoring individuals.

Yihan Li (Sciex)
Dr. Yihan Li is currently an Application Scientist at Sciex. She obtained her Ph.D. at University of Washington, working on the development of CE-MS for proteomics research. She then received her postdoc training at Northwestern University where she focused on MS method development for top-down proteomics. Dr. Li worked at the proteomics core facility at University of Hawaii before joining SCIEX in 2015. Her unique experience in both bottom-up and top-down protein characterization and quantification allow her to design various strategies to achieve high sensitivity for both intact quantification and signature peptide analysis.

Suk Hyung (Genentech)
Dr. Suk Hyung is a Scientist in the Bioanalytical Sciences Department at Genentech. Currently, his research has been primarily focused on the development of bioanalytical assays to support antibody-drug conjugates programs utilizing mass spectrometry. These contributions have enabled a better understanding of the stability and biotransformation of ADCs in vivo. Prior to joining Genentech, Dr. Hyung was a postdoctoral fellow at Pfizer and holds a Ph.D. in Chemistry from the University of Cambridge. He has authored more than 20 publications.

Jintang He (Genentech)
Dr. Jintang He is currently a Scientist in the BioAnalytical Sciences department at Genentech. He is responsible for developing high resolution mass spectrometry methods to characterize in vivo biotransformations of antibody-drug conjugates. He received his Ph.D. in Biochemistry from Peking University. He then completed his first postdoctoral training in proteomics at University of Michigan – Ann Arbor, and pursued further training in mass spectrometry at Pacific Northwest National laboratory. Dr. He joined Genentech in 2014 and his research interests include characterization of ADC biotransformation and quantification of protein therapeutics.